Predicting future risk of asthma exacerbations using individual conditional probabilities

Background Determination of future risk of exacerbations is a key issue in the management of asthma. We previously developed a method to calculate conditional probabilities (π) of future decreases in lung function by using the daily fluctuations in peak expiratory flow (PEF). Objective We aimed to e...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of allergy and clinical immunology 2011-06, Vol.127 (6), p.1494-1502.e3
Hauptverfasser: Thamrin, Cindy, PhD, Zindel, Joel, Nydegger, Regula, MD, Reddel, Helen K., MBBS, PhD, Chanez, Pascal, MD, PhD, Wenzel, Sally E., MD, FitzPatrick, Susan, BS, Watt, Rosemary A., PhD, Suki, Béla, PhD, Frey, Urs, MD, PhD
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Determination of future risk of exacerbations is a key issue in the management of asthma. We previously developed a method to calculate conditional probabilities (π) of future decreases in lung function by using the daily fluctuations in peak expiratory flow (PEF). Objective We aimed to extend calculation of π values to individual patients, validated by using electronically recorded data from 2 past clinical trials. Methods Twice-daily PEF data were analyzed from 78 patients with severe (study A) and 61 patients with poorly controlled (study B) asthma. For each patient, the π value was calculated from 5000 PEF data points simulated based on the correlation and distribution properties of observed PEF. Given an initial PEF, the π value was defined as the probability of a decrease in PEF to less than 80% of predicted value on 2 consecutive days within a month. These probabilities were then compared with actual occurrences of such events and clinically defined exacerbations within the following month. Results π Values were related to actual occurrences of decreases in PEF (adjusted R2 > 0.800 for both studies). Every increase of 10% in π value was associated with an odds ratio of having a future exacerbation of 1.24 (95% CI, 1.07-1.43) for study A and 1.13 (95% CI, 1.02-1.26) for study B, with better sensitivity and specificity than clinic-measured FEV1. Conclusion These results from 2 independent datasets with differing asthmatic populations and differing exacerbation criteria provide support that clinically relevant quantification of individual future risk of exacerbations is possible.
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2011.01.018